Compare iShares MSCI India ETF (INDA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI India ETF trades at $49.68, while Twist Bioscience Corp trades at $125.79 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | TWST | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $125.21 |
52-Week Low | $45.42 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% with a bullish technical signal supported by moving averages. The ETF tracks India's market, which grew 7.8% in Q1 2026 (CNBC, June 5, 2026), but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Key support and resistance cluster around $50.
Outlook remains mixed: India's strong economic growth offers long-term potential, but near-term risks include Middle East disruptions affecting exports (Reuters, August 4, 2026) and AI-driven pressure on IT firms. Institutional sentiment is cautious amid foreign capital rotation.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
